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Predicting the future is a difficult task. Not surprisingly, there are many examples and assumptions that have
proved to be wrong. This review surveys themany predictions, beginning in 1887, about the future of laboratory
medicine and its sub-specialties such as clinical chemistry andmolecular pathology. It provides a commentary on
the accuracy of the predictions and offers opinions on emerging technologies, economic factors and social
developments that may play a role in shaping the future of laboratory medicine.
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1. Introduction
Attempting to predict the future or being dogmatic about what may
or what may not transpire in the future is a risky business, and history
provides numerous examples of predictions and assumptions that
have proved to be wrong.
Spectacularly inaccurate predictions abound in the field of consum-
erism and computing. In 1966, Time magazine stated, “Remote shop-
ping, while entirely feasible, will flop” [1]. In 2012, the US online retail
sector had total revenues of more than $200 billion, with a compound
annual growth rate of 11.0% between 2008 and 2012 [2]. The launch
of the iPod drew the following comment from the founder of a major
consumer electronics company in 2005: “Next Christmas the iPod will
be dead, finished, gone, kaput” [3]. By January 2007, the iPod USmarket
share of digital music player sales had reached 72.7% [4]. In 2007, the
CEO of Microsoft advanced the opinion that “There's no chance that
the iPhone is going to get any significant market share. No chance” [5].
By the end of fiscal year 2010, a total of 73.5 million iPhones had been
sold [6].
The early days of computing also produced some famously errone-
ous predictions. In 1943, the chairman of IBM said, “I think there is a
world market for maybe five computers” [7]. Another highly respected
member of the early computer industry, the president, chairman and
founder of Digital Equipment Corp., explained in 1977, “There is no
reason anyone would want a computer in their home” [3]. Despite
these predictions, a US Department of Commerce survey from 2011
showed that 75.6% of households in the United States reported having
a computer [8]. In fact, computer makers shipped more than 85 million
computers in the second quarter of 2012 [9], and the worldwide PC,
tablet and mobile phone combined shipments were approximately 2.2
billion that same year [10].
The prognosticator usually bases predictions on contemporaneous
information and perceived trends. Picking the relevant trends and
identifying transformative technologies is generally more of an art
than a science. For example, an emerging and ultimately successful
technology can be at any of a number of stages of development, and
these can influence the perception of its influence and contribution to
future developments. These stages, characterized by the Gartner Hype
Cycle, include “a peak of inflated expectations”, “a trough of disillusion-
ment” and end with “a plateau of productivity” [11]. Clearly, greater
weight likely will be attributed to the future influence of a technology
when it is at the peak of inflated expectations, compared to when it
has descended into a trough of disillusionment.
Many authors have offered predictions regarding the future of labo-
ratorymedicine and its subspecialties. This article reviews the literature
that prognosticates on the future of laboratory medicine and provides a
2014 perspective of the future of laboratory medicine.
2. Predictions for the future of laboratory medicine
There is no shortage of predictions about the future of laboratory
medicine. These fall into two categories; the first category includes gen-
eral predictions for the future while the second represents predictions
for specific dates in the future (Table 2) [12–48].
An interesting starting point is the Inaugural lecture, titled “A view
from a bridge,” given in 1969 by Tom Whitehead, the first Chair of
Clinical Chemistry at the University of Birmingham [16]. He identifies
five eras of clinical chemistry: The complicated era from 1920 to 1940
when testing was manual and laborious, the simplified era from 1940
to early 1950s when test procedures were simplified, the crisis era in
the late 1950s when the test workload doubled every 4–5 years, the
sophisticated era in the late 1960s based on new automation and
computing technology, and the profile era in the 1970s when tests
were bundled together as profiles in order to improve laboratory
efficiency and to detect biochemical abnormalities that would not
have been detected by clinical examination (Table 3). He also points
to the continuing importance of computers and automation, in addition
to the emergence of preventative medicine and pharmacogenetics.
There ismerit in each of these predictions. For example, profiling has
re-emerged in clinical testing in the form of protein, tissue and nucleic
acid arrays (e.g., cytokine profiles, array comparative genomic hybridi-
zation analysis) [49–52]. Computers and automation have played an in-
creasingly important role in improving the efficiency and effectiveness
of testing. More recently, pharmacogenetics, popularized by the slogan
“right patient, right drug, right time” [53], has moved into mainstream
testing (e.g., CYP2C9 for warfarin dosing) [54].
Since 1969, there have been many predictions and views of the
future development of laboratory medicine and its sub-specialties. A
summary of these predictions is provided in Table 1 [12–48]. A number
of common themes and buzz-words can be identified in the prognosti-
cations such as nanotechnology, biosensors, microchips, genomics, and
proteomics. These topics, together with the more specific predictions,
are discussed in greater detail below.
2.1. Laboratories, laboratory organization and staffing
Early publications predicted “as many as two workers in the labora-
tory” at largemedical centers and specified that the roles of laboratorian
and pharmacist would be combined [15]. By 1989, the emphasis had
shifted to concerns about the impending shortages of pathologists [24],
a concern that has continued into the 2000s [33].
In more recent times, futurists have predicted a world dominated by
large supra-regional tertiary centers or laboratory networks formed by
laboratory consolidation [35,46]. Contraction in the number of laborato-
rieswould be driven by out-sourcing of laboratory services, competition
between laboratories for hospital work, and the commoditization of
laboratory tests [28,34,35]. A positive trend would be possible growth
due to refocusing of clinical laboratory services due to changing demo-
graphics (e.g., emphasis on diseases of the elderly and reassessment of
location of services) [28]. Within laboratories, integrated services
staffed by clinical laboratory scientists may lead to further contraction
(e.g., hematology, transfusion medicine, biochemistry and immunology
merged into a unified “blood sciences”) [46]. Staff would be responsible
for demand management, greater components of user education and
the provision of additional consultative services related to laboratory
testing. In the context of increased point-of-care testing, the future
role of laboratorians would be reduced to maintaining equipment and
performing quality control [19]. Other predictions focus on the
challenges of global harmonization of in vitro diagnostic tests, reducing
laboratory errors and eliminating unnecessary testing [33].
Early predictions for the scale and scope of clinical laboratories
(e.g., a total of two workers in the laboratory) were off the mark (see
Fig. 1 that contrasts a clinical laboratory in 1904 and 2014). However,
predictions about a combined laboratorian pharmacist may have been
accurate 100 years later with the advent of personalized medicine
[55]. More importantly, predictions on laboratory consolidation have
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Table 1
Predictions for laboratory medicine made on a specific date or about specific dates and periods in the future.
Predictions made on a specific date about the future
Predictions made in 1887 [12]
• Improved methods for examining living tissues, ex vivo.
• Microscopy will be improved to visualize structures that cannot be seen.
Predictions made in 1889 [13]
• Use of the microscope and chemical methods will aid in discovering the mechanisms of diseases.
Predictions made in 1906 [14]
• “The future is, no doubt, to the pathologist, and if diagnosis, prognosis, and treatment of disease are to depend mainly upon blood examination and bacteriology, the general
practitioner may have to carry out these examination himself or sink to the level of a mere collector and transmitter of blood and sputum, while the consulting pathologist
pulls the strings of the treatment.”
Predictions made in 1920 [15]
• Laboratory professionals who do not directly interact with patients would be paid entirely by a fixed salary.
• Clinicians with direct contact would be paid fee for service.
• Primary service of laboratories is to the general clinical practitioners “to enable him personally to make any examinations he desires to undertake”.
• Skill level of the director varies with medical center size, geographic location and specialization.
• Larger medical centers may combine the roles of laboratorian and pharmacist.
• At the largest medical centers, as many as two workers in the laboratory may be necessary.
• Communication between laboratory centers will be by telephone or motor vehicle.
• The laboratory specialties will include morbid anatomy, bacteriology and pathological chemistry.
• The health services laboratory will be separate, but in close contact with the ‘professorial department’.
• “No rigid barrier should be erected between the academic pathologist and those engaged in the health services”.
Predictions made in 1969 [16]
• Emergence of toxicogenetics and pharmacogenetics in the context of preventative medicine.
• Greater use of automation and computers.
Predictions made in 1970 [17]
• Doctors' offices, hospitals and clinical laboratories will share information “on-line” through a remotely located computer.
• ‘Automated ordering’ — 1. doctor writes a lab order; 2. order is given to a receptionist; 3. receptionist calls the patient and the laboratory to schedule a phlebotomy
appointment; 4. appointment slip is typed on a typewriter in duplicate (one copy for the patient and one for the office record); 5. the typewriter updates information to the
remotely located computer; and 6. the remotely located computer generates a daily work list via automated typewriter at the laboratory.
• Patient records are centrally located in the computer.
• Entire medical record can be sent to another city via punched paper tape or automated typewritten hardcopy.
• Physicians may review documents via video terminal (standard telephone line service is cited to soon be as fast as one page per 2 min at a cost of $8.50 per month).
Predictions made in 1978 [18]
• Analytical systems capable of testing for hundreds and thousands of different substances.
• Development of human molecular anatomy.
• On the verge of a cataclysmic revolution in terms of the complexity of data generated.
Predictions made in 1980 [19]
• Point of care testing and the proliferation of diagnostic kits.
• Empowerment of patients to perform tests previously only done by trained clinical chemists.
• Laboratory methods will be developed that sleep-deprived surgeons can perform in an acceptable manner.
• Future role for laboratorians in maintain equipment and performing quality control.
Predictions made in 1985 [20]
• Testing will become decentralized into doctor's offices and patient rooms.
Predictions made in 1985 [21]
• Clinical laboratory testing will become decentralized, but the decentralization will not improve the interpretation of test results.
• Chemical pathologists will become a specialist like radiologists using chemical analysis instead of X-ray imaging. They will develop methods to solve patient problems and
become more of specialist and less of a manager.
• Hospital based laboratory testing will disappear and be replaced by centers of testing outside of the hospital.
Predictions made in 1986 [22]
• The success of laboratory medicine depends on not only analytical performance but also ordering practices and reporting.
• The future of laboratory medicine will be guided by cost containment.
• New technologies such as DNA hybridization cross many traditional laboratory specialties and may require a new management structure for effective utilization.
Predictions made in 1987 [23]
• Advances in technology allow for consolidation of multiple laboratory specialties: chemistry, toxicology, hematology, microbiology and immunology.
• Consolidation and centralization of laboratory specialties will have financial benefits.
• Miniaturized and automated technology enables laboratory technology to be deployed closer to the patient (e.g., emergency rooms, physician offices, patient homes).
• Automated laboratory tests will decrease the need for professionals with analytical skills, but will increase the need for managers that operate and integrate new laboratory
technologies in a cost-effective manner.
Predictions made in 1989 [24]
• Shortage of pathologists in community hospitals in the United States predicted to reach between 400 and 600 FTE by 1992.
• Predicts increasing retirement, decreasing trainees, expansion of technology and an aging population requiring more laboratory services.
Predictions made in 1990 [25]
• Robotics, biosensors and micromachine technology, neonatal genetic screening.
Predictions made in 1990 [26]
• Improved chromatographic and immunological techniques, novel types of mass spectrometry, biosensors, in vivo nuclear magnetic resonance spectroscopic probes, new
intracellular probes, new types of toxicological assays, advanced computer and information technology.
Predictions made in 1994 [27]
• Universal automated immunoassay analyzers, standardization of immunological measurements, number and specificities of immunological analytes to increase, antigens
produced by recombinant DNA techniques, more functional analyses, development of less-complex tests.
Predictions made in 1995 [28]
• Clinical chemist to develop cross-disciplinary expertise and become a clinical laboratory scientist.
• Consolidation and integration of clinical laboratories.
• Out-sourcing of laboratory services.
• Competition between laboratories for hospital work.
• Increased automation, transport modules to deliver specimens to analyzers. Personalized reference intervals.
• Artificial intelligence for result interpretation.
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Table 1 (continued)
Predictions made on a specific date about the future
• Widespread use of DNA probes.
• Intracellular metabolic studies based on fine needle biopsies and FACS.
• In vivo blood gas, oximetry and bilirubin measurements.
• Refocusing of clinical laboratory services due to changing demographics (emphasis on diseases of the elderly and reassessment of location of services) Expanded role for
noninvasive diagnosis (e.g., nuclear magnetic resonance of whole body or organs, probes for the mouth and other body cavities).
Predictions made in 1996 [29]
• Distributed systems based on client/server computer architecture.
Predictions made in 2000 [30]
• Expanded use of database software for genomic and proteomic screening to increase efficiency of clinical assay development.
Predictions made in 2001 [31]
• Counter-top gene sequencers for predicting effectiveness of drugs.
• Endorsement and reimbursement of laboratory testing as a “predict-and-manage” strategy.
• Increased demand for clinical laboratory services as population ages.
• Consumerism encourages more medical testing.
• Digital solutions (electronically distributed lab test results).
• Increased automation and computer-based analysis.
• Chronically ill and homebound maintain a continuous record of lab data preserved on personal electronic medical record.
• Online access to laboratory test results.
Predictions made in 2004 [32]
• Entering era of molecular diagnostics and pathology; pharmacogenetic and pharmacogenomic testing.
Predictions made in 2006 [33]
• Staff shortages.
• Increase in point-of-care testing, home testing and noninvasive testing.
• Increased use of tandem mass spectrometry.
• Increased use of molecular diagnostics (chips, SNPs, single cell analysis).
• Use of robotics.
• Telecommuting.
• Challenges will include global harmonization of IVDs, nanotechnology, reducing laboratory errors and unnecessary testing, population demographics, international
competition in healthcare.
Predictions made in 2007 [34]
• New business model for the operational organization of clinical laboratories based on consolidation, integration, and virtual laboratories.
• Commoditization of tests.
• Provision of additional knowledge services relating to testing.
Predictions made in 2010 [35]
• Laboratory networks.
• Commoditization of laboratory tests.
• Greater components of user education and demand management.
Predictions made about specific dates or periods in the future
Predictions made in 1977 about 1982–1987 [36]
• Automation, non-isotopic immunoassays, HPLC-based analyses, GC–MS-based assays (fingerprinting microorganisms), multicomponent analysis (metabolic profiles), cell
sorting.
Predictions made in 1980 about 1981–2001 [37]
• Computer assisted interpretation of tests.
• More computer capacity for monitoring of quality and plausibility
• Increased concern with data interpretation and organizational problems.
Predictions made in 1985 about 1986 to 1995 [20]
• Growth of drug monitoring and clinical immunology.
• Laboratory testing will move closer to patients with direct testing of patients in operating rooms, intensive care units and patient rooms.
Predictions made in 1985 about 1990 to 1995 [21]
• Clinical laboratory testing will become decentralized.
Predictions made in 1988 about 1993 to 2008 [38]
• Technology of mapping and sequencing the human genome will take another 5–10 years and sequence of human genome will take from 10 to 20+ years.
Predictions made in 1993 about 2000s [39]
• Important role of miniaturization, molecular biology, whole blood assays, and more sensitive instrumentation.
Predictions made in 1995 about 2000–2005 [40]
• Continued evolution of front-end specimen management systems.
• Non-invasive instrumentation.
• Advances in cellular diagnostics, image analysis and immunocytometry, DNA probes, amplification technology and quantitative techniques on easy-to-use instruments.
• Viral load monitoring and new tests for management of cancer and central nervous system disorders.
• Microchips and micromachines transform instrumentation.
• Multianalyte detection (DNA microchips).
• Diagnostic instruments to become portable, simple and flexible.
• In vivo imaging with antibody fragments.
• Innovation driven by the electronic superhighway (e.g., voice-activated recognition systems).
• Addition of hundreds of possible diagnostic tests based on the human genome project.
• Smaller, lower-cost point of care instruments with built-in quality control systems and very broad menus.
• Increase in role of near-patient testing (5–10% of all testing by 2000).
Predictions made in 1996 about 2001–2006 [41]
• Computers report laboratory data with graphics.
• Image storage and transmission of reports.
Predictions made in 1996 about 2006–2016 [41]
• Focus on preventative medicine.
• Integration of molecular medicine, information and computer technology.
• Predictive tests (risk factors).
(continued on next page)
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been on point, as evidenced by the rise of national reference laboratories
such as ARUP, Quest Diagnostics and LabCorp. In addition, over the past
fifty years, some have predicted that the development of miniaturized
point-of-care testing devices would de-centralize laboratory testing. If
we consider the large direct-to-consumer market for patient testing
(blood glucose, pregnancy testing, urine analysis) and doctors' office
testing, perhapswe see two simultaneous trends: consolidationof tradi-
tional laboratory testing and an expanding newmarket for near-patient
testing.
The identification of cost containment as a major factor in the future
of laboratory medicine was correct [22], as well as an emphasis on the
cost-effective operation of laboratories [23]. There is a continuing
trend to unify independent hospitals into Health Systems and to consol-
idate specialty laboratories (e.g., immunology, microbiology and
chemistry) into a Core Laboratory model. In many parts of the world,
the laboratory services for geographic regions andwhole nations are co-
ordinated to serve vast populations. One prominent example is the
establishment of the Calgary Laboratory Services (CLS) in Alberta,
Canada [56]. In 1994, the health authority of Alberta began consolidat-
ing healthcare services for the city of Calgary and its surrounding
regions. The consolidation included the closure of hospitals and central-
ization of laboratory services. By the end of 1995, there was a sole pro-
vider for all laboratory services in the Calgary region. A central principle
guided the organization of laboratory services: all tests with a
turnaround time of N2 h were centralized into a single high volume
laboratory. Only STAT or urgent testing capabilities remained in the
hospital-based laboratories. Today, two decades later, this single entity
continues to coordinate laboratory services for a metropolitan region
with a population of over a million people.
The prediction for “blood science” laboratories also has been correct
as evidenced by the Blood Science Laboratory at the University Hospital
BirminghamNHS Foundation Trust in the UK. This brand-new automat-
ed laboratory combines chemistry, immunoassay, serology, transfusion,
blood counts/films, and coagulation testing [57].
Table 1 (continued)
Predictions made about specific dates or periods in the future
• Miniaturization of analytical devices and DNA chip technology.
• Strong influence from molecular biology, genomics, combinatorial chemistry, robotics, micro electronics and informatics, pharmacogenomic profiling, nanotechnology.
• Large-scale hyperlinked data banks for patient care and new informatic tools and systems (algorithms for data mining, databanks for gene-disease risk correlations,
encryption methods to ensure privacy and confidentiality).
• Mass spectrometry for protein expression profiles.
Predictions made in 1997 about 2007–2017 [42]
• Technologies with greatest impact — molecular diagnostics, near patient testing (via biosensors), image analysis, robotics, information management (telepathology, voice
recognition, hand-held devices for test ordering/result retrieval).
Predictions made in 1999 about the third millennium [43]
• Importance of diagnostic gene chips and nanotechnology.
Predictions made in 2000 about 2001–2009 [44]
• Nanotechnology enables micrototal analytical systems, single cell analysis
• Greater integration of point of care testing into patient management strategies and pathways of care.
• Pharmacogenomics to allow individualized dosing with drugs.
• Proteomic studies provide basis for future diagnostic tests.
• Evidence based medicine combined with experience-based medicine to provide effective route for diagnosis and treatment.
Predictions made in 2002 for 2003–2012 [45]
• Transformation of healthcare science and the regulation and training of staff.
Predictions made in 2006 about 2026 [46]
• Laboratories organized as large supra-regional tertiary centers and local centers (large private laboratory providers dominate).
• Large pharmaceutical companies and private laboratory services to provide pharmacogenomic and metabologenomic services in the home.
• “All-contained drop-down” modules will feature prominently in new laboratories to offer flexibility and expandability.
• High dependence on robotics, automated specimen handling, automated specimen tracking and humanoid technology.
• European consortium to bring together public and private laboratories to develop vital sign technology (telemedicine).
• Telemedicine, remote controlled microscopy, artificial intelligence microscopy, internet communication, remotely accessible telepathology workstation platforms.
• Artificial intelligence automated cytoscreening technology.
• Nuclear magnetic resonance microscopy (cellular metabolo-imaging).
• Integration of hematology, transfusion medicine, biochemistry and immunology into a unified “blood sciences”.
• Specimen identification chips (Spec-Chip) incorporate sample identification and patient record within the sample cuvette.
• Semi-permanent implanted personal profile chip for detection of disease signatures in peripheral blood.
• Diagnostic nano-robots for monitoring of disease.
• Population microgenomics.
• Lab-on-a-chip devices for microbiology and infectious disease testing
• Hand-held devices for top eight infectious pathogens will be available for monitoring.
• High-density SNP diagnostic assays commonplace (e.g., for profiling tumors).
• High-density antibody and protein chip arrays for immune disease testing and assessing immune response.
• Individual patient genome signature profiling commonplace.
• Twenty-four color chromosome karyotyping/spectral analysis of tumors routinely offered in hematological malignancies and solid tumors.
• Electrochemical detection of infectious agents, gene mutations, specific gene transcripts and proteins using devices in a primary healthcare setting.
• Microelectromechanical (MEMS) devices used to inoculate individual red cells in vivo.
• Nanoparticles used to seek out specific cells.
• Nano-encapsulation and nano-robot technology for drug delivery.
• Smart medical implants using biosensors and fuel cells (active real-time autonomous monitoring).
• Implantable radiofrequency identification (RFID) microchips.
• Humanoid technology in use in laboratories.
Predictions made in 2012 about 2013–2017 [47]
• Slow introduction of pharmacogenomic testing into primary care
• Focus of genomics research and application will shift into the primary care setting
• Increase in consumer demand for pharmacogenomic testing
• Primary care theranostics to become a significant portion of healthcare
Predictions made in 2012 about 2020 [48]
• Smartphone (or a tablet device) as the hub of medicine
• Smartphone-enabled portable laboratory (lab-on-a-chip devices)
• Individuals who have had their genome sequenced increasingly common
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The concern for laboratory staffing shortages is likely to continue. A
2012 ASCP survey in the US showed vacancy rates of 7% in core labs [58,
59]. Findings such as these may hasten strategies to reduce staffing
needs, namely consolidation and automation. However, some types
of consolidation, such as combining Radiology and Pathology, seem a
remote prospect.
Declining reimbursement for laboratory tests will force laboratories
to take further measures to reduce expenses, which may include a
major role for test triage by laboratory professionals. But, over ordering
of tests and inappropriate test requests will be difficult to control and
enforce in the absence of penalties for offenders. Laboratory utilization
models that have emerged in the past decade include laboratory formu-
laries (e.g., University of Michigan, Brigham & Women's Hospital and
University of Rochester Medical Center) [60,61] and restricted access
or uniform denial of access to tests deemed to have limited value
(e.g., Calgary Laboratory Services) [62]. An important component of
the success of these strategies is the management and enforcement by
stakeholders outside of the laboratory. In the case of laboratory formu-
laries, the chief medical officer and chief operating officer of the health
system manage some of the recently implemented models. With the
rise of international access to medical care services for expensive elec-
tive procedures, such as cardiac and orthopedic surgery, some experts
have proposed the possibility of outsourcing clinical laboratory services
to countries with equally sophisticated laboratory services, but signifi-
cantly lower costs (e.g., labor and infrastructure) [63]. Indeed, there
are continued efforts for international harmonization of laboratory test-
ing quality programs and regulations through ISO (The International
Standards Organization), CAP (College of American Pathologists) ac-
creditation and CLIA (Clinical Laboratory Improvement Amendments)
certification.
In addition to outsourcing and globalization of laboratory testing,
there has been an increased migration of testing to the point-of-care.
This transition may decrease reliance on hospital laboratories and
reduce test volumes in hospital or regional laboratories. Empowering
consumers through a wider range of home tests may further decrease
test volumes in laboratories. Although it is possible that empowering
consumers via deregulation of direct-to-consumer testingmay increase
overall test volumes, predicting the consumer response to a large menu
of newly accessible diagnostic tests remains difficult at this time.
The internet has made information about disease and its diagnosis
easily available. This widespread access to health-related information
has spawned a new class of patients seeking to influence decisions on
their healthcare (sometimes called “junior MDs”). New resources,
such as Lab Tests Online, provide patients with extensive information
about laboratory tests [64]. Similar to how physicians and laboratory
professionals can access internet search engines, such as Google, to
learn about the ordering and interpretation of the latest esoteric tests,
patients also can readily investigate the tests they desire and the various
interpretations. In the case of complex testing (e.g., genomics) that
requires massive and constantly updated databases, companies have
demonstrated consumer/patient interest in direct access to testing and
its interpretation.
By better informing the patient, the internet may actually drive
down the cost of laboratory testing.Multiple clinical laboratory test pro-
viders offer direct-to-consumer testing for a wide menu of tests. Not
only will these direct-to-consumer tests increase patient options, but
some providers also specify test prices. In the United States, patients
are becoming more familiar with healthcare costs; laboratory testing
will not be an exception. Therefore, it is anticipated that this increased
level of patient education likely will lead to a class of better-informed
and more-demanding patients in the future.
Table 2
Predictions made about medicine and healthcare.
Predictions made in 1900 about 2001 [183]
• Few drugs will be swallowed — drugs will be applied directly to organs through
the skin and flesh via an electric current applied without pain to the outside skin
of the body.
• Microscopes will lay base the vital organs, through the living flesh, of men and
animals. The living body will to all medical purposes be transparent using rays of
invisible light.
Predictions made in 1955 about 1999 [184]
• 150-year life span, infectious disease eradicated, cancer treated using a vaccine,
surgical techniques to restore sight, deaf–mute to speak electronically.
Predictions made in 2012 about 2020 [185]
• Organ printing (aka bio-printing, bio-manufacturing or computer-aided tissue
engineering), synthetic blood, personalized medicine to provide the right drug
to the right patient at the right time, stem cell treatments
Predictions made in 2012 about 2022 [186]
• Nanoparticles will make chemotherapy far more effective by delivering tiny
doses of drug right to cancerous cells.
• Your genome will be sequenced before you are born
• Drugs will be tested on “organ chips” that mimic the human body.
• Genetic testing will be used to halt epidemics. Vaccines will wipe out drug
addiction.
Predictions made in 2012 about 2030 [187]
• Life expectancy of 150 years
Predictions made in 2012 about 2032–2062 [186]
• Checkups will be conducted by cell phone.
Predictions made in 2012 about 2063–2122 [186]
• Your body will be truly connected and your vital signs checked around the clock
via tiny sensors
• Stomach chips will monitor your diet to help you lose weight
• Spinal cord implants will reverse paralysis
• Brain chips will let you absorb data while you sleep
• Brain interfaces will help you fully inhabit virtual worlds
Predictions made in 2013 about 2014 [188]
• Rise of telemedicine — “the virtual doctor will see you now”
• Shop for your health care — greater price transparency and consumerism
• Expanded mental health care coverage
• Side-effects of the physician shortage — boomers may lose their doctors
• More at-work clinics — see a doctor during your work break
Predictions made in 2013 about 2045 [189]
• Brain implants unlock the power of the cloud
• Functional brain map leads to post-brain-map era
• Immortality is real — brain kept alive in a robotic surrogate or uploaded to silicon
Table 3
Eras in clinical chemistry and genetic testing.
Era Clinical chemistry testing Clinical genetic testing
Complicated era —manual and tedious 1920–1940; clinical use of measuring hematologic
parameters and blood chemistries
1977–1986; Sanger sequencing using radioactive reagents
Simplified era — simplified test procedures 1940s; laboratory instrumentation introduced 1987–2000; automated Sanger sequencing of single genes or point
mutations (fluorescent reagents)
Crisis era — test workload doubling every 4–5 years 1950s; clinical laboratory testing becomes routine 2001–2009; post-human genome project, many genes do not have
a clinical test available
Sophisticated era — testing based on new
automation and computer technology
1960s; automated chemistry analyzers 2010–present; next-generation sequencing applied to panels of genes
Profile era — tests bundled together as profiles to
improve efficiency and detect abnormalities not
detected by clinical exam
1970s–1984; multi-analyte analyzers 2012–present; next-generation sequencing applied to exome and
whole genome
Commoditization era — testing is routine and is
perceived as a commodity selected by quality and cost
1985–present To be determined
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Another consideration is that disruptive technologies may lead to
dramatic changes. One company that currently is being predicted to
change the delivery of laboratory services is Theranos [65]. The
Theranos technology has been a closely guarded secret, which at the
time of this publication is unknown. Reportedly, the technology allows
up to 70 different tests, performed on a 25 to 50 μL blood sample obtain-
ed from a finger stick, to be available within hours. The implementation
of the technology will be through high-complexity CLIA-certified
laboratories and Theranos plans to seek FDA clearance for it tests. It
has teamed-up with a national pharmacy chain (Walgreens) to create
blood collection centers (“Wellness Centers”) in 21 of the 8200
Walgreens stores across the United States. Another feature of the
Theranos business model is that it purposes to charge less than 50% of
the standard Medicare and Medicaid reimbursement rates. This de-
creased charge is predicted to save Medicare $98 billion and Medicaid
$104 billion over the next ten years [66]. Clearly, success of the Theranos
technology and test delivery model would be disruptive for both
hospital- and reference laboratory-based testing.
2.2. Automation and robotics
The evolution of automation and roboticmethods in laboratories has
been a popular prediction that includes front-end specimen manage-
ment systems and automated specimen tracking [40,46].More futuristic
predictions describe transport modules to deliver specimens to ana-
lyzers and the use of humanoid technology [28,46]. “All-contained
Fig. 1. Clinical laboratories then and now. A. Otto Folin in the biochemistry laboratory at McLean Hospital in 1905 (photo by A.H. Folsom (Harvard) http://en.wikipedia.org/wiki/Otto_
Folin#mediaviewer/File:1905_Otto_Folin_in_biochemistry_lab_at_McLean_Hospital_byAHFolsom_Harvard.png). B. Automation Laboratory at the University of Pennsylvania Medical
Center, Philadelphia, PA, USA in 2014.
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drop-down” modules (a fully operational analyzer in the form of a
module) feature prominently in new laboratories to offer flexibility
and expandability (46).
The various predictions about the growth of automationmostly have
been correct. Many fully automated track and front-end specimen pro-
cessing systems have been installed in clinical laboratories (N2700
installed in the US as of 2013) [67]. However, the notion that humans
could be replaced with humanoid robots in the laboratory of the future
has not become a reality. The current capabilities of humanoid robots
are limited, but they certainly have the potential to do the types of
tasks currently performed by humans (e.g., ASIMO from Honda and
MOTOMAN from Yaskawa Electric) [68,69] (Fig. 2).
Although predictions for the use of automation may have been cor-
rect for clinical chemistry and hematology, automation and robotics
have been slow to move into other areas of the laboratory such as
microbiology, molecular pathology, and anatomic pathology. Also, un-
anticipated automation has occurred in the development of software.
Middleware now allows for communication between analyzers,
information systems and electronic medical records. The transfer of
specimens from phlebotomy, to the laboratory, and then to analysis
and result can be monitored in real-time. This has led to improved
capabilities in quality management and efficiency.
It is expected that the demand for automation and/or robotics will
increase, not only for cost efficiency, but also for maintenance of consis-
tent, skilled specimen handling. The agingworkforce has negatively im-
pacted the availability of skilled laboratoryworkers, and there aremany
workforce predictions that highlight the future shortage [70]. In
addition to becoming cheaper and easier to implement, robotics may
be essential for laboratories of all sizes as the workforce shrinks. Hu-
manoid robots are continuing to improve in their scope of capabilities
(e.g., vision, tactile sensing, whole-body motion, manipulation). There-
fore, it is not unreasonable to foresee a disruptive role for suchmachines
in the laboratory of the future [71].
An obvious area for improvement is the simplification of the analyzer–
human user interface. Operation of analyzers remains relatively com-
plex, and thus necessitates operators with a specific level of education
and training. Simplification of the operator interface would provide
both improvements in quality and the opportunity to employ less
well-educated, and hence less costly, staff.
Overall, technology will continue to fuel the adoption of automated
work systems in the clinical laboratory. Within the past twenty years,
there has been surprising adoption of automation into cytology
(Focalpoint) [72], microbiology laboratories (BD Kiestra — automated
microplating, culturing and identification) and anatomic pathology
(Ventana Symphony— automated H&E slide-staining platform) [73].
2.3. Computing and information technology
In 1978, wewere thought to be on the verge of a cataclysmic revolu-
tion in terms of the complexity of laboratory test data generated [18].
Several authors have pointed to the future development of large-scale
hyperlinked data banks for patient care (e.g., databanks for gene-
disease risk correlations), distributed systems based on client/server
computer architecture, and generally, innovation driven by the
electronic superhighway [29,40,41]. Others have anticipated the use of
artificial intelligence for result interpretation (e.g., automated cyto-
screening), encryption methods to ensure privacy and confidentiality,
voice recognition, and hand-held devices for test ordering/result re-
trieval [41,42,46]. A component of test ordering potentially may include
implantable radio-frequency identification (RFID) microchips to
facilitate facile and unambiguous patient identification [46].
Some predictions have pointed to improvements in data interpreta-
tion and presentation such as personalized reference intervals, expert
systems [74] and the reporting of laboratory data with graphics.
Computing and information technology have come to underpin
many aspects of laboratory medicine, and there is now a wide utiliza-
tion of computers (data transmission, interpretation, manipulation,
graphical reporting) and sophisticated information technology (IT)
technology (remote servers, cloud computing). Concern about the secu-
rity of health information has led the US federal government to enhance
existing legislation of health information security (HIPAA — Health
Insurance Portability and Accountability Act) in order to improve
healthcare data security and specify protections of genetic data under
HITECH (Health Information Technology for Economic and Clinical
Health Act) [75]. One consequence of the maturation of IT technology
has been that laboratory data is now directly available to consumers;
this accessibility has been mandated by U.S. law [75].
The last ten years has seen the emergence of healthcare informatics
and the application of computational algorithms to large data reposito-
ries. This has paralleled the tremendous growth in big data— the use of
data warehouses, data management and analytics across many indus-
tries, not just healthcare [76]. The NIH established the eMERGE
Fig. 2.A. Humanoid robot ASIMO (Honda) (reproducedwith permission fromHondaNorth America). B. Two-armed humanoid robotMOTOMAN (Yaskawa Electric Corporation)working
at the bench (reproduced with permission from Yaskawa Electric Corporation).
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(ElectronicMedical Records andGenomics)Network in 2007 to fund re-
search that combines DNA biorepositories, electronic medical records
and genetic research [77]. Thismulti-institutional collaborative explores
the use of genetic variation data into genetic risk assessment, preven-
tion, diagnosis and treatment of disease. In addition, healthcare centers
such as Memorial Sloan-Kettering Cancer Center are partnering with
sophisticated information technology resources such as IBM's Watson
supercomputer to develop novel methods of diagnosing and treating
disease [76].
It is interesting to note that the utilization of computing power has
gone through stages. In the 1970s, the use of telephonewires to commu-
nicate data to a central computer was the model. Also, typewriters and
punched paper tape played a prominent role in the process [17]. By the
1990s, desktop computers or computers embedded in or adjacent to an-
alyzers hadbecome commonplace. Now, in 2014,wehave a combination
of portable devices, desktop computers and workstations all working in
conjunction with centralized servers or cloud-based services.
Artificial intelligence currently is used extensively. Some examples
include result interpretation via auto-verification programs, testing
algorithms that reflex to separate orders based on initial results, and in-
terpretations based on unifying the results of multiple tests (e.g., gene
signatures) [78]. In addition, voice recognition is commonly used in
anatomic pathology practice [79].
As anticipated, data encryption has assumed considerable impor-
tance, especially in the context of safeguarding electronic health infor-
mation in the cloud [80]. Improved computational power has not only
enabled interpretation of genomics data, but has also revealed the
possible difficulties in ensuring privacy of genetic information. Recent
studies have demonstrated the power of comparing genetic informa-
tion, surname and other personal identifiers to deduce the identity of
a sequenced individual [81].
Predictions about the development of data banks also proved to be
correct. Today there are numerous genetic and protein data banks
accessible via the internet (e.g., GenBank, dbSNP, HGMD, ClinVar, The
Protein Data Bank) [82–84].
Enthusiasm for implantable radio-frequency identification (RFID) mi-
crochips was well placed. In 2004, the FDA approved the VeriChip
implantable RFID device [85]. Unfortunately, the VeriChip was
discontinued in 2010 due to lack of commercial success. Other RFID tags
have been better received and are used to tag patient specimens (blood
tubes, tissue cassettes, identifying wristbands) [86] and components of
analyzers and automation systems (e.g., Gen-Probe fluid containers,
Beckman Coulter pucks) [87,88].
Based on the advances over the last fifty years, we almost certainly
can predict that computing power, memory capacity, networking and
portability will improve. In fact, Moore's law has successfully predicted
the doubling of data approximately every 18 months [Moore's law].
These hardware advances, together with innovative software, will en-
able further miniaturization of analytical devices, create new analytical
tools for quality control, and also create new tools for predicting future
health based on current medical information [89].
One emerging computer-enabled technology is 3D printing that can
be used for rapid manufacturing of a three-dimensional object. This fa-
cilitates distributed manufacturing and has the potential to cause a sea
change in the way in which equipment and consumables are sourced
by clinical laboratories in the future [90].
As computing becomes more routine, there will need to be height-
ened awareness of errors that potentially put patients at risk. The risk
of undetected mistakes will grow as algorithms and processes become
more complex and automated. Indeed, a recent scandal involving faulty
diagnostic expression profiling (revealed by a forensic bioinformatic
study) [91,92] has resulted in recommendations from the Institute of
Medicine (IOM) on future test development and implementation [93].
The IOM investigation concluded that complex technologies have errors
that are either unintentional (mistakes) or intentional (fraud) that are
difficult to detect or control.
2.4. Analytical techniques and technologies
Several authors have made generalized predictions regarding the
future of analytical techniques and technologies (Table 1). These in-
clude new types of toxicological assays, new tests for the management
of cancer and central nervous system disorders, increased number and
specificities of immunological analytes,more functional analyses, devel-
opment of less-complex tests, advances in cellular diagnostics, image
analysis and immunocytometry, and intracellular metabolic studies
based on fine needle biopsies and fluorescence-activated cell sorting
(FACS) [26–28,40]. A few specific methods have been singled-out as
important in terms of the future of laboratory medicine such as non-
isotopic immunoassays, HPLC-based analyses, tandemmass spectrome-
try (MS), GC–MS-based assays, nuclearmagnetic resonancemicroscopy
(NMR) (cellular metabolo-imaging) and cell sorting [33,36,46].
In addition, the laboratory of the future has been envisioned to
have more standardized methods (e.g., standardized immunological
measurements) [27].
In vivo assays also have been identified as an attractive future ana-
lytical direction. Some examples are in vivo nuclearmagnetic resonance
spectroscopy, imaging with antibody fragments, blood gas testing, ox-
imetry and bilirubinmeasurements, endomicroscopy, optical coherence
tomography and smartmedical implants using biosensors and fuel cells
(active real-time autonomous monitoring) [28,40].
Noninvasive testing is a long-cherished goal. Future prospects have
included noninvasive instrumentation and an expanded role for nonin-
vasive diagnosis (e.g., nuclear magnetic resonance of whole body or
organs, probes for the mouth and other body cavities) [26,28].
Predictions related to an increase in the type of tests have been a safe
bet (e.g., new types of toxicological assays, new tests for the manage-
ment of cancer and central nervous system disorders). Likewise, predic-
tions about the growth of non-isotopic immunoassays, HPLC-based
analyses, GC–MS-based assays have been correct. Technologies that
have been integrated into current clinical practice include intracellular
metabolic studies (based on fine needle biopsies, FACS) and nuclear
magnetic resonance microscopy (NMR) (cellular metabolo-imaging,
1H-NMR metabolonomic profiling of cancer tissue) [94]. Smart medical
implants also have becomea reality, as exemplifiedby theGuardian sys-
tem for real-time continuous monitoring of glucose via an embedded
sensor in a thin needle placed under the skin [95].
Noninvasive testing has made some, albeit slow, progress. Infra-red
(IR)-based methods for oxygen determination are now commonplace
(e.g., pulse oximetry), noninvasive multiple wavelength reflectance-
based bilirubin measurement in neonates has become established in
clinical practice (SpectRx BiliCheck) [96], and nuclear magnetic reso-
nance probes for body cavities (e.g., rectal probes) have been developed
to image the prostate [97]. There also has been an emergence of
novel sources for biomarkers such as saliva and breath testing
(e.g., Metabolomx breath test for lung cancer based on volatile organic
compounds) [98].
Another issue related to emerging technologies is the sudden inter-
vention by a regulatory agency. A case in point is direct-to-consumer
genetic testing (e.g., 23andMe). Initially, this type of testing flourished,
but the FDA determined that 23andMe was “marketing the 23andMe
Saliva Collection Kit and Personal Genome Service (PGS) without mar-
keting clearance or approval in violation of the Federal Food, Drug and
Cosmetic Act” and that it must “discontinue marketing the PGS until
such time as it receives FDA marketing authorization for the device”
[99]. The FDA action against 23andMe is a reminder that regulators
manage a balance between safety and innovation. Sometimes this
balance will tip toward loose regulatory policy to foster innovation.
However, in the interest of public health and/or safety, regulatory policy
may tighten and inadvertently stifle innovation. Most recently, the FDA
has issued a draft guidance to register and actively regulate laboratory
developed tests (http://www.fda.gov/downloads/MedicalDevices/
ProductsandMedicalProcedures/InVitroDiagnostics/UCM407409.pdf).
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If this guidance is passed without major changes, it may dramatically
change the development of esoteric tests in the United States.
A potential threat to many analytical methods is interference by
hemoglobin in blood substitutes. If widespread clinical use of blood
substitutes becomes a reality, the associated interference will render
current chemistries inoperable. A possible solution would be to transi-
tion from UV–visible-based methods to IR-based analytical methods,
as hemoglobin is transparent in the IR. IR-based methods for common
chemistry analytes already exist [100]; however, the extent of hemoglo-
bin interference in clinical specimens has not yet reached a critical level
that would necessitate a change in methods.
A more distant analytical prospect is noninvasive testing for a
broader range of analytes. This is a long-held goal but the ultimate
prize of an effective noninvasive glucose monitor remains elusive.
Nevertheless, noninvasive glucose testing, despite numerous setbacks,
continues to be the focus of much research [101].
2.5. Point-of-care testing
Many views of the future of laboratory medicine include a trend to-
ward more testing at the point-of-care (or near to the patient), greater
integration of point-of-care testing into patient management strategies
and pathways of care, and more testing in the home [44]. The recent
growth in point-of-care testing has been facilitated by low-cost, porta-
ble, simple and flexible hand-held devices with built-in quality control
systems and very broad menus. Specific predictions point to hand-
held devices for monitoring the top eight infectious pathogens [46]. In
terms of ease of operation, one described target user is the “sleep-
deprived surgeon”; therefore, one important goal of method develop-
ment is ease of use [19].
A trend towardmore testing at the point-of-care has been a safe bet,
as has the trend towardmore testing in the home. Although the predict-
ed point-of-care device for monitoring the top eight infectious patho-
gens is still not available, currently there are simplistic devices (for
doctor's office or hospital use) that can detect N20 of themost common
respiratory viral pathogens within hours (e.g., BioFire FilmArray) [102].
Many of the analytical systems used in the clinical laboratory
have corresponding portable applications (electrolytes, hematology,
blood gas, immunoassay, molecular diagnostics, flow cytometry, mass
spectrometry) that can be used at the point-of-care. Limitations for
widespread use of these devices are analytical reliability, cost, conve-
nience and regulatory approval.
The rate of development of point-of-care devices is such that novel
analytical technologies have the potential to decentralize laboratories.
For example, if the cost of specific point-of-care tests, such as available
on iSTAT, decreased to that of core-laboratory testing, the devolution
of testing from the central laboratory to the point-of-care might occur
rapidly.
One category of testing device that continues to advance is thewear-
able device. Two important examples of wearable wireless sensors
include the Google contact lens for glucose testing [103] and the
Triggerfish contact lens for monitoring glaucoma [104]. Other wearable
sensors exist in the form of clothing (intelligent textiles) [105] or a
tattoo (smart tattoos for glucose testing) [106].
Yet another type of wearable device is a watch. The GlucoWatch is
an early example of a watch-like device designed to measure glucose
[107]. Recently, Samsung announced a smart watch that will monitor
vital signs [108]. Stand-alone modules, such as the Scanadu Scout vital
sign monitor, are poised to influence the scope of testing in the home
[109]. The slogan for the Scanadu device is “Check your health as easily
as your email,” which perhaps targets a generation of consumers that
has grown up with computers, the internet, smartphones and tablets.
Interestingly, the inspiration for many of these types of devices can be
traced to the Star Trek Tricorder, an example of life imitating art.
Phones can perform analyses at the point-of-care using plug-in
modules that take advantage of the computing and communication
features of a computer. In the mid-2000s, there were cell phones
modified by the addition of a reader (e.g., LG KP8400 phone with
blood glucose monitor, and the GlucoPhone) [110]. Subsequently, the
glucose meter component evolved into a USB stick-like device that
could plug into the USB port of a computer (e.g., CONTOUR NEXT USB,
Bayer) [111]. Most recently, the meter component plugs directly into
the adapter port of a smartphone or tablet (e.g., iBIGStar connects to
any Apple iOS device) [112].
Contrary to many predictions, hand-held devices in the form of
smartphones and tablets are only slowly entering the mainstream of
healthcare. However, there has been growing enthusiasm for phone de-
vices that take pictures of slides and tissues, perform colorimetric tests,
and readily provide on-board data analysis. Indeed, smartphones have
become a platform technology perfectly suited for low-resource or
remote settings within health networks [113].
The evolution of telecommunications, portable devices and
smartphones has changed what is possible in low resource settings.
Fifteen years ago, there was a focus on low resource infectious disease
testing (e.g., tuberculosis). At the time, microscopy for examining
sputum samples for acid-fast organisms was difficult in low resource
settings because it required staining equipment, a microscope, and a
skilled microscopist. This need was met by the successful development
of molecular devices such as the Cepheid cartridge-based system for
Mycobacterium tuberculosis [114]. In current times, smartphones can
be enabled with simple adaptors to become powerful microscopes
with submicron resolution that can detect single viral particles [115].
Images obtained from either a conventional or smartphone microscope
can be sent via a smartphone app for remote viewing and interpretation
by a pathologist (The UPMC Pocket Pathologist App) [116]. Thus, in a
low resource setting, an alternative to sophisticated molecular diagnos-
tic devices may be minimally skilled providers who require only an en-
hanced smart phone and a reliable method to process a sputum sample
and take a picture. Continuing innovations in telecommunications and
portable devices may one day render even the most sophisticated
laboratory-based technologies obsolete.
2.6. Telemedicine
Telemedicine and telepathology, which are the practice of medicine
facilitated by digital transmission of data, feature in a number of predic-
tions for the future of laboratory medicine [42,46]. Aspects of internet-
enabled telemedicine include remote-controlled microscopy (linked
to artificial intelligence) and remotely accessible telepathology work-
station platforms. A European consortium is envisaged to bring together
public and private laboratories to develop vital sign technology
(telemedicine) [46]. Telemedicine-related predictions also focus on a
smartphone or a tablet device; these types of devices are predicted to
become the hub of medicine in the future [48].
In theUnited States, themilitarywas an early adopter of telepathology
and remote pathology [117]. Telepathology is now in place in many
clinical laboratories [118]. In addition, dedicated home systems for both
the collection and transmission of medical data from wireless devices
are available from a number of companies (e.g., Viterion TeleHealthcare
100 BGM TeleHealth Monitor [119], Phillips TeleStation [120]). These
types of systems collect and transmit a range of vital signs including
blood pressure, pulse, blood oxygen, weight, temperature, and blood
glucose.
The use of telepathology for themanual interpretation of differential
blood counts has become routine with systems such as CellaVision
DM1200, which scan and facilitate the interpretation of blood smears
[121]. CellaVision represents a successful model for telepathology:
(i) there are multiple sites with automated slide preparation and slide
scanning, (ii) images are loaded into a centralized or cloud-based server
and (iii) interpretation by laboratory professionals and physicians oc-
curs from any internet-accessible location. The use of telepathology in
routine surgical pathology has not yet occurred, but scanning systems
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that convert pathology slides into digital images are now common place
for teaching, research and consultative practices. In addition, although
digital slide scanning systems for primary diagnosis of surgical patholo-
gy have not yet gained regulatory approval in the United States,
slide scanning systems for primary pathology diagnosis have gained
regulatory approval outside the United States. The prediction that a
smartphone, tablet or other portable device can become the hub of
medicine has become a reality with real-life examples of doctor–patient
encounters, static image examination and whole slide imaging.
The advantages of telehealth include reduction in hospital
readmissions, improved clinical outcomes and reduction in long-term
health costs. These are sufficiently compelling tomake telehealth an im-
portant component of the future of health care. Also, it is expected that
emerging smartphone telehealth applications will develop alongside
the home station technology.
Two key regulatory guidances provided by the US FDA have created
clear paths for the clinical implementation of digital pathology (slide
digitization, accessing and interpretation) andmedical software on por-
table devices (mobile medical apps) [122,123]. Although the initial re-
ception has been tepid from proponents of these technologies, the
pathway to commercialization has becomemuch clearer. It is inevitable
that these imaging systemswill enable slide interpretations acrosswide
geographic areas. Indeed we can anticipate that this will enable further
consolidation of surgical pathology testing and interpretation. Indeed,
themajor anticipated obstacles to remote interpretation will be regula-
tory issues such asmedical licensure [124]. Issues of interstate licensure
Fig. 3. A. The lab-on-a-chip concept (© 2006–2014 PerkinElmer, Inc. Reproduced with permission). B. Nanorobot for atherosclerosis plaque removal in vivo (reproducedwith permission
Nanobotmodels Medical Animation, Svidinenko Yuriy —www.nanobotmodels.com).
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in the United States are being anticipated by the development of a
proposed interstate licensure compact [125].
2.7. Microtechnology
The technological advances that accompany the miniaturization of
analytical devices are a dramatic change from the traditional analytical
techniques used in laboratorymedicine [23,126]. The focus ofmicrotech-
nology has been on “lab-on-a-chip” devices (Fig. 3A). Some examples of
these include chips for specimen identification (e.g., incorporates sample
identification and patient record within the sample cuvette), semi-
permanent implanted personal profile chips for detection of disease
signatures in peripheral blood, high-density antibody and protein chip
arrays for immune disease testing, and DNA chips. Microchips and
micromachines assembled using micro-electromechanical (MEMS)
technologies are predicted to transform analytical instrumentation [27].
Miniaturized analytical devices, e.g., “lab-on-a-chip” devices, have
not lived up to their hype and relatively few have found routine use in
clinical analysis. Exceptions include DNA arrays (e.g., Affymetrix arrays,
Illumina bead arrays) [127,128] and protein array chips [129]. Themore
futuristic vision for specimen identification chips that incorporate
sample identification and the patient record within the sample cuvette
has not reached fruition.
The scope and extent of research on microminiaturization,
microfluidics and total integration of assays onto a chip is enormous,
and it is difficult to believe that this ultimately will not yield a large
number of analytically useful devices. However, the emergence of non-
invasive techniques could herald the decline of devices that rely on a
sample. In the absence of such a paradigm shift, some notable current
developments focus on the combination of reagent-coated microbeads
and arrays of reaction vessels, especially in the context of single mole-
cule counting (digital) immunoassays and PCR. This type of technology
underlies an emerging generation of ultrasensitive immunoassays that
can detect proteins present at ultralow levels [130].
2.8. Nanotechnology
The analytical advantages that might be realized from miniaturiza-
tion at the nanometer scale have captured the imagination of many
prognosticators [41]. Applications include nanoparticles that seek out
specific cells and analytical systems for single cell analysis [44,46].
More futuristic visions include diagnostic nano-robots for monitoring
of disease [46] (Fig. 3B).
Nanotechnology has not had as large of an impact on diagnostics as
waspredicted. The futuristic vision of diagnostic nano-robots for disease
monitoring was originally proposed in 1959 by Albert Hibbs [131]. This
general idea is embodied in the recently developed “Bacteriobot” that is
a genetically modified, non-toxic, motile salmonella bacterium armed
with sensors to detect chemicals released by cancer cells [132]. Practi-
cally, nanoparticles as labels or solid phases (e.g., for capture antibodies
or probes) provide the largest area of application (e.g., 13–20 nm
reagent-coated particles used in the Nanosphere Verigene System)
[133].
Nanotechnology is the subject of a large and diverse range of
research; therefore, it is expected that nanotechnology ultimately will
have amajor impact on analyticalmethods. Innovations in nanotechnol-
ogy have produced a diverse range of nano-sized objects with analytical
utility including nanoparticles (quantum dots), nanofibers, nanowells,
nanopores, nanorods, nanotubes, nanoprisms, nanochannels, and nano-
wires. Nanostructured materials also are beginning to find analytical
uses (e.g., nanostructured magnesium oxide-chitosan for genosensing)
[134]. However, safety-related concerns have surrounded the manufac-
ture and implementation of nanomaterials, especially carbon nano-
tubes. This may hinder the future use of some nanomaterials [135].
2.9. Genomics
In general, many predictions for the future of laboratory medicine
highlight the importance of molecular diagnostics and the integration
of molecular medicine, information and computer technology. The
emergence of toxicogenetics and pharmacogenetics, in the context of
preventative medicine, had been predicted as early as 1969 [16].
Subsequently, genomics (e.g., pharmacogenetic and pharmacogenomic
testing and profiling) has been featured in a number of views of the fu-
ture, especially in the context of facilitating individualized drug-dosing
regimens. The use of pharamacogenetic information to guide therapeu-
tic decisions (theranostics) is predicted to become a significant portion
of healthcare [117]. One view of the future envisions that both large
pharmaceutical companies and private laboratory services will provide
pharmacogenomic and metabologenomic services in the home [46].
Methodology-based predictions focus on viral load monitoring,
high-density SNP diagnostic assays (e.g., for profiling tumors), neonatal
genetic screening, twenty-four color chromosome karotyping/spectral
analysis (e.g., hematological malignancies and solid tumors), wide-
spread use of DNA probes, electrochemical detection of infectious
agents, genemutation analysis, gene and protein profiling using devices
in a primary healthcare setting, and quantitative amplification technol-
ogy on easy-to-use instruments. In addition, the completion of the
human genome project is predicted to fuel the development of
hundreds of possible new diagnostic tests [40].
A key component of genomics is sequencing technology. In 1988,
Leroy Hood proposed that the first phase of technology development
would take 5–10 years, and that sequencing of the human genome
would take between 10 and more than 20 years to complete [38]. More
current prognostications believe that the number of individuals who
havehad their genome sequencedwill increase in the future, and individ-
ual patient genome signature profiling will become commonplace.
In the area of genomics, incorrect estimates for the number of genes
and the function of DNA have misinformed predictions. The original es-
timate for the number of genes in the human genomewas 6.7million, a
far cry from the current estimate of approximately 20,000 genes [136].
Likewise, the discovery that “junk” or “non-coding” DNA maintains
functionality has transformed DNA sequencing and interpretation
efforts [137]. It seems reasonable to expect that junk DNA will be a
rich source of discovery that will have a significant impact onmolecular
diagnostics in the future.
Predictions overestimated the time it would take to complete the se-
quencing of the human genome. The original US Department of Energy
and the National Institutes of Health $3 billion project was founded in
1990 and expected to take 15 years. In reality, the draft sequence was
completed in June 2000, followed by the publication of a working
draft in 2001 [138]. In general, predictions about the importance of
the human genome project and molecular diagnostics have been
correct.
Over the past decade, the emergence of next-generation/massively-
parallel sequencing has revolutionized DNA sequencing [139]. For now,
the clinical applications of large-scale sequencing have been limited to
the testing of rare diseases and tumors for the off-label use of drugs.
As predicted high-density SNP diagnostic assays have become com-
monplace. The first FDA-cleared microarray system was the AmpliChip
Cytochrome P450 genotyping test (Roche-Affymetrix) [140]. This
system detects 31 DNA variants in the cytochrome genes CYP2D6 and
CYP2C19. In 2014, the FDA cleared the Cytoscan HD high density SNP
array (Affymetrix) for use in the diagnosis of developmental delay,
intellectual disability and congenital anomalies [141].
Other examples of specific tests and methodologies that are now
common in clinical use include viral load monitoring (e.g., HIV, CMV,
HPV), DNA probes, neonatal genetic screening, and quantitative ampli-
fication technology on easy-to-use instruments (e.g., GeneXpert) [140].
The predicted twenty-four-color chromosome karotyping/spectral
analysis (e.g., hematological malignancies and solid tumors) now exists
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[142], as does nucleic acid-based electrochemical detection of infectious
agents [143]. Both are limited in their routine application.
Home genetic testing services (from either pharmaceutical compa-
nies or private laboratories) have not been developed. The closest anal-
ogy would be some of the direct-to-consumer tests (e.g., 23AndMe SNP
testing) [144]. We also have not arrived at a future in which large
numbers of individuals have had their genome sequenced and individ-
ual patient genome signature profiling has become commonplace. As of
June 2012, there were only 69 complete human genome data sets pub-
licly available [145]. However over amillionmore are currently planned
(UK 100,000 genome project [152] and the BGI one million human
genomes project [153]).
Pharmacogenomic testing has been implemented slowly over the
past decade. An increase in consumer demand may drive utilization in
the primary care setting. The predicted provision of pharmacogenomic
services is now a reality. Express Scripts, the largest pharmacy benefit
manager in the United States, has a personalized medicine program
that identifies patient eligibility for specialty drugs based on genetic
testing. Indeed, this new model of personalized medicine utilizes the
pharmacist to interpret genetic results to determine pharmaceutical se-
lection [55,146]. The use of pharmacogenetics to guide individualized
drug selection and dosing has been controversial and has not reached
wide adoption. One exception is drug selection in the context of
targeted therapy in oncology — this has become readily adopted in the
past decade and is expected to grow. Unfortunately, there are few
examples of sustainable remission on targeted therapy.
The use of genomic methods, such as expression profiling, has had
limited success. In the 1990s, there was a NCI director challenge to re-
place histological interpretation and classification of tumors by RNA-
expression profilingmethods onDNAmicrochips (Fig. 4). Subsequently,
there have been some tremendous commercial successes by companies,
such as OncotypeDX [147], that offer RT-PCR based profiling of multiple
mRNAmarkers to predict future risk of breast cancer recurrence and de-
termine additional adjuvant chemotherapy. Agendia (MammaPrint) is
another example of a company that has commercialized tumor profiling
[148]. The FDA responded to the development of these types of complex
multimarker tests with guidance known as IVDMIA (In Vitro Diagnostic
Multivariate Index Assay). Although the guidance was drafted in 2007,
it is still not finalized 7 years later [149], and not all clinically available
expression profiling tests have complied with IVDMIA. Expression
profiling certainly has not replaced histologic diagnosis and traditional
cancer classification systems, but has become an ancillary test to guide
therapy. Indeed, a recent medical research fraud case has resulted in
an IOM investigation and guidance for further regulation of complex
tests such as expression arrays [150].
In 1969, Whitehead described the evolution of clinical chemistry
through several eras of development [16]. The development of other di-
agnostic testing such as genetic testing has undergone similar phases of
development as illustrated in Table 1. A new era to consider, which was
not anticipated, is one of commoditization. In this new era, testing is
considered routine and laboratory management and cost containment
are key drivers.
It seems that pharmacogenomics will continue to struggle to main-
tain relevance in the future. Poor adoption, even in the context of clinical
benefit, suggests that unless there are external pressures, this type of
testing will not increase. However, the implementation of personal
credit card-sized pharmacogenetic profile cards illustrates one way in
which pharmacogenomics could evolve in the future (Fig. 5).
Next-generation sequencing will make DNA testing readily avail-
able, but we are still in the early implementation phase of this technol-
ogy, and its clinical utility remains questionable [151]. Several large
clinical studies are anticipated to provide insight into the link between
Fig. 4.Microarray technology for simultaneous study of the expression ofmany genes fromnormal and tumor tissue. Each gene “chip”has thousands of gene sequences in known locations.
A sample containing DNA or RNA is placed in contact with the gene chip and binding is detected via fluorescence. Areas on the chip producing fluorescence identify genes that are
expressed in the sample. (Credit: Darryl Leja, NHGRI; https://www.genome.gov/dmd/img.cfm?node=Photos/Graphics&id=85200).
296 L.J. Kricka et al. / Clinica Chimica Acta 438 (2015) 284–303
Author's personal copy
DNA sequence and disease. Two examples are the UK 100,000 genome
project [152] and the Beijing Institute for Genomics (BGI) Million
genome project [153].
A critical factor thatwill affect the future of genetic testing is the con-
tinued fall in the cost of sequencing (Fig. 6). In 2001, the cost perMbwas
N$5000. By October 2013, the cost had plummeted to $0.057 [154]. The
$1000 genome had remained a futuristic goal that reached fruition in
2014 with the launch of the Illumina HiSeq X Sequencer [155]. At the
current time, the HiSeq X costs $10 million per unit and can sequence
a whole genome for $1000 (when the capacity of 20,000 per year is
met). As a theoretical consideration, every year in the United States, ap-
proximately 4 million newborns undergo genetic and/or metabolic
screening tests for potentially harmful or fatal conditions [156]. If
these newborns instead were tested by whole genome sequencing, we
potentially couldmeet the national need for the vast majority of genetic
testing usingHiSeq X instrumentation. In fact, 200 HiSeq X instruments,
each running 20,000 samples per year, could meet all of the newborn
testing needs, although additional genetic testing may be necessary in
a subset of the population (e.g., the selection of therapeutic modalities
in patients that develop cancer). This “HiSeq X newborn screen” may
seem to be an extreme approach with a price tag of $4 billion per
year. However, predictions by the US health insurer United Healthcare
indicate that, by 2021, the United States will spend between $15 and
$25 billion per year on genetic testing. A HiSeq X national infrastructure
for newborn genomic sequencing may be a relative bargain.
Currently, a $1000 genome does not include the costs of interpreta-
tion, long-term data storage and other infrastructure needs, but it is
now a realistic number that is far cheaper than most complex genetic
tests [157]. The subject of population genomic testing is no longer an an-
alytical fantasy, but a reality that must be dealt with by society; society
Fig. 5. Personal credit card-sized pharmacogenetic profile card (images courtesy of Professor Ron van Schaik, Erasmus MC, Rotterdam, The Netherlands).
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may not want this test outside of the context of disease treatment and
management. The major remaining barriers to massive population se-
quencing include unresolved quality and regulatory and ethical issues.
There is more than one philosophical approach toward the future of
whole genome sequencing: an optimistic perspective would be that
whole genome andwhole exome sequencingwill have utility in healthy
populations and will predict future health, while a pessimistic perspec-
tive would be that whole genome sequencing has limited application
outside of ultra-rare pediatric diseases and will be limited to research
applications. The current mainstream view on genomics is that the
market is unlimited; all individuals potentially will have their genome
sequenced at birth, and every patient with a new cancer diagnosis will
have his tumor DNA and RNA sequenced and profiled.
2.10. Proteomics
Proteomics, similar to other types of “omics”, is envisaged to provide
the basis for future diagnostic tests. Predictions describe the develop-
ment of analytical systems capable of testing for hundreds and thou-
sands of different proteins. For example, mass spectrometry has been
identified as a method to generate protein expression profiles [41].
One interesting foundation for the future of proteomics is the devel-
opment of humanmolecular anatomy, based on the NIH-AECMolecular
Anatomy Program designed to dissect human cells at the molecular
level. This was an ambitious goal that relied on high-resolution analyti-
cal methods such as two-dimensional electrophoresis (e.g., ISO-DALT).
The Molecular Anatomy Program sought to catalog the complete set of
proteins expressed in humans (The Human Protein Index), and hence,
systematically explore gene regulation and misregulation [158].
In recent years, the varieties of “omics” have proliferated, and
predictions regarding the importance of different types of omics, such
as proteomics and genomics, have been well founded.
Diagnostic protein assays slowly have been added to the menu of
routine tests (e.g., troponin I, BNP). In addition, the importance of mass
spectrometry (MS) for generating protein profiles has been borne
out by the new, recently FDA-approved, MS-based microorganism
identification systems (e.g., BioMerieux VITEK MS system [159] and
Bruker MALDI Biotyper CA [160]).
The total number of proteins in human cells is estimated to be
between 250,000 and 1,000,000 [161]. It is a reasonable expectation
that many of these as yet unstudied proteins could be the basis of a
newdiagnostic test, either singly or as part of amultiplex test.Multiplex
protein assays, in a two-dimensional planar array or a liquid (suspen-
sion) array format (e.g., collections of microbeads), continue to be the
focus of attention and are expected to becomemore common if the pro-
tein signature approach to analysis continues to grow [162]. Detection
remains a challenge for proteins present at very low concentrations.
However, the new generation of digital immunoassays may provide
the required technology [130,163]. The path forward for protein bio-
markers and protein-based multiplex assays also has been improved
by specific recommendations for the biomarker development,
evaluation and validation process [164,165].
2.11. Evidence-based medicine
When combined with experience-based medicine, evidence-based
medicine has been predicted to provide an effective route for diagnosis
and treatment [44]. Laboratory testing represents the single-highest
volume clinical activity and underpins much of clinical decision-
making [166]. The role of evidence-basedmedicine is to provide the ev-
idence base for the use of laboratory investigations in clinical practice.
The emphasis on the importance of evidence-based medicine has
been well founded, and there has been sustained interest and activity
in this field [167,168]. The National Institute for Health and Care Excel-
lence (NICE) provides an example of evidence-based decisionmaking in
healthcare; this UK-based organization offers diagnostic guidance about
various tests and diagnostic pathways (NICE Evidence Services) [169].
In theUS, the CDChas developedprograms in Evidence-Based Laborato-
ry Medicine that are intended to “systematically identify, develop, and
pilot test laboratory medicine evidence-based quality/performance
measures to improve public health with measureable laboratory
practices which are safe, timely, efficient, effective, equitable and
patient-centered” [170].
Fig. 6. The falling cost of sequencing—Moore's Law for genetics [Wetterstrand KA. DNA Sequencing Costs: Data from the NHGRI Genome Sequencing Program (GSP) Available at: www.
genome.gov/sequencingcosts. Accessed [July 2014]].
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Concern continues to mount over healthcare spending in the US. At
17.4% of the GDP in 2009, this figure is considerably higher than health
care spending in any other country [171]. Rising health care costs
are not sustainable, and the evidence-based medicine approach, via
identification of best practices, may be one way to improve healthcare
and reduce costs.
2.12. Microscopy and histopathology
The future role of microscopic examinations clearlywas emphasized
as early as 1887 [12] and again re-emphasized in subsequent years [13].
More recent views of the future envisage themarriage of artificial intel-
ligence, microscopy and nuclear magnetic resonance microscopy [46].
Tissue analysis using a microscope has continued to be a resilient
technology, which has stayed relatively unchanged for hundreds of
years. In the late 1990s, the demise of surgical pathology was predicted
with the rise of expression profiling of tumors [172]. This did not
happen. In fact, surgical pathology remains the dominant technology
for the diagnosis and classification of cancer. Nevertheless, the emer-
gence of digital pathology and whole slide imaging has the potential
to change the practice of pathology by adding analytical tools and alter-
ing workflow and interpretation [173]. Automated imaging systems,
such as FocalPoint and CellaVision, are commercial successes that have
changed the workflow of clinical laboratories [72,121].
The predicted shortage of pathologists has not materialized, and the
most recentworkforce study indicates a current surplus—however, this
is predicted to become a shortage in future years [174]. The pathologist
workforcewill change in parallelwith the nature of thework to be done.
For example, the autopsy is a key service traditionally performed by
pathologists, but the number of autopsies performed has fallen in the
United States (50% decline from 1972 to 2007) [175]. This has been
off-set by a concomitant rise in small tissue sampling such as fine-
needle aspirations and endoscopic biopsies.
Digital pathology will increase the efficiencies of training and daily
practice by enabling faster training of future pathologists. In addition,
the digitization of slides holds the possibility of distributing workloads
amongst multiple physical centers separated by state and national
boundaries.
The Ontario Health Network is one model for the efficient deploy-
ment of surgical pathologists. In this model, there are centers of highly
specialized pathologists in dense population areas in proximity to
specialized centers of care. These specialized pathologists work in con-
junction via digital pathology and telecommunication networks with
more generally trained pathologists to cover a vast geographic area
[176]. As digital pathology becomes routine, the workforce require-
ments for pathology are predicted to increase; however, efficiency will
also increase as caseloads can be balanced betweenmultiple geographic
sites. Furthermore, the workforce will segment into generalists who
maintain community hospitals and perform activities that cannot be
done remotely (apheresis, fine needle aspirations, laboratory manage-
ment) and specialists who sit in a communications center interpreting
digital images and providing consultations to generalist pathologists
and clinicians.
The Pap smear for cervical cancer screening has historically been a
high volume test for pathologists and cytologists globally. With the ad-
vent of automated imaging systems, such as FocalPoint [72], there has
been a decrease in the number of cervical Pap smears evaluated by
humans. In addition to automation of standard Pap smears, recent
clinical guidelines [177] have suggested that molecular HPV infection
evaluation may substitute for microscopic examination of cervical
cells. In 2014, the FDA approved the use of the Roche Cobas HPV test
as a first line primary screening test for cervical cancer [178]. Further-
more, the implementation of HPV vaccination in the United States
will decrease the rate of HPV infection and abnormal Pap smears that
require evaluation.
Endomicroscopy [179] and high-field strength nuclear magnetic
resonance (NMR) [180] have micron level resolution and are in clinical
use globally. Although these methods have not replaced microscopy,
further advances in these minimally invasive imaging tools may erode
the need for microscopy of tissue specimens.
3. Predictions for laboratory medicine in regions and countries
In addition to the US, specific predictions and plans for the future of
laboratory medicine have focused on other countries. In 1997, views on
the future of the European Clinical Laboratory were explored by means
of questionnaire answered by 31 national representatives [181]. The
most frequently cited future challengeswere implementationof request
strategies, interpretative reports and pre-analytical aspects of analysis.
The survey also revealed that respondents believed that information
technology and new scientific developments would make the greatest
impact, and that, in the future, economic pressure would be a major
limiting factor on the activities of laboratories in spite of an anticipated
increase in the number of tests.
In 2009, the Royal Belgian Society of Clinical Chemistry noted that
hospital laboratories are being endangered by an increasing trend to
outsource clinical laboratory tests to external laboratories [182].
It advocated proactive measures to increase efficiency and reduce
costs by consolidation (e.g., formation of regional networks). It also
commented that laboratory staff should refocus their efforts to provide
medical knowledge services to clinicians.
In England, a prescription for the future of pathology and laboratory
medicine can be found in the Pathology Modernization Programme
launched in 1999, and in the subsequent Carter review published in
2006 [183]. So far there has been limited progress toward the visions
for the future of pathology and laboratory medicine formulated in
1999 (e.g., managed pathology networks) or in 2006 (e.g., stand-alone
pathology service providers, end to end IT connectivity including
point-of-care testing).
4. The future of laboratory medicine in the context of the future of
medicine and healthcare
Laboratory medicine exists within the broader framework of medi-
cine and healthcare. Therefore, changes and advances in these areas
will impact the future direction of laboratory medicine. Predictions
made about medicine and healthcare, beginning in 1900 and reaching
nearly 50 years into the future, are detailed in Table 2 [184–190]. The
majority of the predictions are optimistic, and they predict more effec-
tive treatments, eradication of disease and a longer lifespan. Common
themes in these futuristic visions are genetic testing and chips to facili-
tate real-time monitoring. For the period 2032–2062, a central role is
predicted for telemedicine [186]. If these predictions are accurate,
then the current rise in implanted sensors and telemedicine forebodes
that central laboratory testing will play a lesser role in the future.
Others have identified megatrends in global health care [191] and
innovations that will transform medicine [192]. The 12 megatrends
are shown in Fig. 7. Finance and the management of limited resources
are factors underlying many of the predicted trends [190]. Ten innova-
tions identified in 2010 that were predicted to transform medicine in
the future include: 1) checklists (e.g., strict protocols for procedures);
2) behavioral economics (e.g., peer pressure to change how doctors
work); 3) patient portals (secure web connections for consumers
to manage their health care); 4) payment innovations (schemes that
reward good outcomes); 5) evidence-based decision making; 6) ac-
countable care organizations; 7) regenerative medicine (e.g., stem
cell-based treatments); 8) virtual visits (videoconferencing and remote
monitoring); 9) genetics enters practice; and 10) surgical robotics [193].
A factor that is sure to have an impact on the future of laboratory
medicine, and healthcare in general, is the aging population. The US
Census Bureau projects that the population will rise to 420.3 million
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by 2060, and that the percent of the population over the age of 65 years
will be 22% (92 million) [192]. Linked to this is the long-term concern
for the continuing growth of health care costs in the US, which are
expected to reach ~20% of GDP by 2021 [194].
Another current US concern is the likely impact of Accountable Care
Organizations (ACO), which are groups of doctors, hospitals, and other
health care providers that focus on the deliverance of cost-effective
and high-quality care [195]. The economic pressures arising from
these changes in healthcare financing and reimbursement also are
anticipated to drive change in the clinical laboratory.
A change in healthcare strategy, such as embodied in P4 Medicine
(Predictive, Preventive, Personalized, and Participatory Medicine),
could impact the types of testing undertaken in the clinical laboratory.
P4 medicine focuses on disease prevention and maintenance of health
and wellness by applying systems biology to medicine [196,197].
Finally, unexpected disruptions could occur as a result of curing of
chronic diseases. If ‘cancer’were to be cured by a novel chemotherapeu-
tic cocktail, thenwhat serviceswould be needed? Eradication of a chron-
ic disease would lead to a dramatic reduction in the number of screening
tests, diagnostic tests andmonitoring tests. The same is true for diabetes.
If type II diabetes could be treated in away that did not require blood glu-
cose monitoring, then there would be minimal need for point-of-care
glucose testing. Conversely, the conversion of fatal diseases into chronic
conditions would expand the need for testing services.
5. Conclusions
The predictions surveyed in this review provide insight into the
changing views about the future of laboratory medicine and its sub-
specialties from 1887 tomodern times.Making predictions is an inexact
science, and so it is not surprising that many of the changes foreseen
have not come to pass. However, prediction is nonetheless important
because it is an integral part of the forward planning process that will
shape the future of all aspects of laboratory medicine.
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